Sulirelin combined with chemotherapy for neoadjuvant/adjuvant treatment of gastric cancer has been recognized by the National Medical Products Administration as a breakthrough therapy.

According to Fuhong Hanlin Company, the innovative PD-1 inhibitor, Sulilumab monoclonal antibody, has been officially included in the list of groundbreaking therapeutic drugs by the National Medical Products Administration's Drug Evaluation Center. It is used in combination with chemotherapy for neoadjuvant/adjuvant treatment of gastric cancer, becoming the first gastric cancer perioperative treatment drug to be recognized as a breakthrough therapy by the CDE. Previously, Sulilumab monoclonal antibody achieved the primary endpoint in phase III clinical studies for this indication, making it the world's first treatment option for perioperative gastric cancer that replaces postoperative adjuvant chemotherapy with immunotherapy alone.